Portal Biotechnologies
Builds universal infrastructure for cell engineering across drug discovery and cell therapy
$9MUndisclosed
Role not disclosedN
NFX
Activity from announced rounds
Activity in this selectionUnited States · Jun 30, 2026 · Jun 1, 2026
NFX is the investment firm identified through founding partner Gigi Levi-Weiss in Remepy’s announcement and through Omri Amirav Drory’s TwoStep relationship.
Recorded funding activity
Remepy combines medicines with therapeutic applications. TwoStep develops targeted cancer therapies, while Starcloud develops orbital computing. The event records identify the firm without inferring a particular fund.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $23M 2 disclosed · full round size, not this investor’s share